Amgen Inc. (FRA:AMG)

Germany flag Germany · Delayed Price · Currency is EUR
232.05
-2.75 (-1.17%)
At close: Sep 26, 2025
-1.17%
Market Cap129.49B
Revenue (ttm)29.73B
Net Income (ttm)5.64B
Shares Outn/a
EPS (ttm)10.41
PE Ratio22.97
Forward PE13.78
Dividend8.59 (3.70%)
Ex-Dividend DateAug 22, 2025
Volume238
Average Volume238
Open234.45
Previous Close234.80
Day's Range231.45 - 235.45
52-Week Range230.00 - 307.05
Betan/a
RSI41.32
Earnings DateNov 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 28,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol AMG
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD Financial Statements

News

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...

4 days ago - CNBC Television

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.

4 days ago - CNBC Television

AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

4 days ago - PRNewsWire

Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition

Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see ...

5 days ago - Seeking Alpha

Amgen: Imdelltra Could Be The Next Game Changer

Despite the political noise coming out of the White House over efforts to lower drug prices, Amgen Inc.'s oncology franchise has continued to deliver strong performance since the start of 2025. So, AM...

6 days ago - Seeking Alpha

Notable Friday Option Activity: AMGN, FTNT, NOW

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN), where a total of 16,898 contracts have traded so far, representing app...

11 days ago - Nasdaq

EMA Backs Amgen Drug For Rare Autoimmune Disorder

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ: AMGN) Uplizna (inebilizumab) to include the treatm...

11 days ago - Benzinga

Gordon Reid's Top Picks: Amgen, Qualcomm & United Rentals

Gordon Reid, President & CEO at Goodreid Investment Counsel, shares his top stock picks to watch in the market.

13 days ago - BNN Bloomberg

‘I fell in love with Dublin’s international atmosphere ... so I decided to stay and build my career in Ireland’

Leire Asua (Accenture) and Hamed Benyounis (Amgen)

13 days ago - The Irish Times

AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

14 days ago - Nasdaq

Noteworthy ETF Inflows: SCHD, AMGN, TXN, LMT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Dividend Equity ETF (Symbol: SCHD) where we have detected an...

15 days ago - Nasdaq

Amgen: Buy The Dip Opportunity

16 days ago - Seeking Alpha

Vanguard Group Inc's Strategic Acquisition of Amgen Inc Shares

Vanguard Group Inc's Strategic Acquisition of Amgen Inc Shares

17 days ago - GuruFocus

Validea Detailed Fundamental Analysis - AMGN

Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Shareholder Yield Investor model based on the published strategy of M...

18 days ago - Nasdaq

Amgen (AMGN) Sees Significant Spike in Investor Interest

Amgen (AMGN) Sees Significant Spike in Investor Interest

19 days ago - GuruFocus

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for a new gastr...

19 days ago - Benzinga

AMGN Sees a Surge in Interest for Its Cancer Therapies

AMGN Sees a Surge in Interest for Its Cancer Therapies

20 days ago - GuruFocus

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...

20 days ago - Reuters

US FDA to step up enforcement of pharma ads, sends enforcement letters

The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi...

21 days ago - Reuters

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ: AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) o...

21 days ago - Benzinga

Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab

Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab

21 days ago - GuruFocus

Amgen (AMGN) Gains Insights from ASCEND Study on Rocatinlimab for Dermatitis

Amgen (AMGN) Gains Insights from ASCEND Study on Rocatinlimab for Dermatitis

21 days ago - GuruFocus

Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ...

Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab for Atopic Dermatitis | AMGN stock news

21 days ago - GuruFocus